VO vs XBI
Vanguard Mid-Cap ETF vs SPDR S&P Biotech ETF
- • VO has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VO pays a higher dividend yield (1.40%).
Side-by-side metrics
| Metric | VO | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.40% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $213.76B | $8.30B |
YTD return | 8.19% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.02 | 1.09 |
P/E ratio | 24.56 | — |
Last price | $77.39 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VO top holdings
| VRT | Vertiv Holdings Co Class A | 1.02% |
| HWM | Howmet Aerospace Inc | 1.00% |
| WDC | Western Digital Corp | 1.00% |
| CEG | Constellation Energy Corp | 0.93% |
| STX | Seagate Technology Holdings PLC | 0.93% |
| PWR | Quanta Services Inc | 0.89% |
| SLB | SLB Ltd | 0.84% |
| CMI | Cummins Inc | 0.81% |
| VLO | Valero Energy Corp | 0.80% |
| PSX | Phillips 66 | 0.79% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VO
VO (Vanguard Mid-Cap ETF) is US mid-cap stocks across sectors. Managed by Vanguard, the fund carries $213.8B in assets under management, an expense ratio of 0.03%, a dividend yield of 1.40%. Its largest holding is Vertiv Holdings Co Class A (VRT), which represents 1.0% of the portfolio. Real Estate is the fund's largest sector exposure at 5.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.